BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
IPO Year:
Exchange: NASDAQ
Website: briacell.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/14/2022 | $25.00 | Buy | HC Wainwright & Co. |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
HC Wainwright & Co. initiated coverage of BriaCell Therapeutics with a rating of Buy and set a new price target of $25.00
8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)
424B5 - BriaCell Therapeutics Corp. (0001610820) (Filer)
8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)
10-Q - BriaCell Therapeutics Corp. (0001610820) (Filer)
8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)
25-NSE - BriaCell Therapeutics Corp. (0001610820) (Subject)
8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)
DEF 14A - BriaCell Therapeutics Corp. (0001610820) (Filer)
SCHEDULE 13G - BriaCell Therapeutics Corp. (0001610820) (Subject)
8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
3 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
3 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
3 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
3 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
3 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
3 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
Fastest customizable press release news feed in the world
PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the closing of its best-efforts offering of 1,449,300 common shares. Each common share was sold at an offering price of $3.25 per share. All of the common shares in the offering were offered by the Company. Total gross proceeds from the offering, before deducting placement agent's fees and other offering expenses, were approximately $4.7 million. The Company relied upon the exemption set forth in Section
Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) patients treated with Bria-IMT regimen selected for Phase 3TWiST analysis, which measures time without disease symptoms or significant treatment-related toxicity, showed clinically meaningful benefit in heavily pre-treated MBC patients in the ongoing Phase 3 studyBiomarker analyses from the ongoing Phase 3 study further validates potential predictors of anti-cancer response initially reported in Phase 2 study 2026 ASCO Annual Meeting, May 29-June 2, 2026, at McCormick Place, Chicago, Illinois PHILADELPHIA and VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWI
PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent's fees and other offering expenses, are expected to be approximately $4.7 million. The offering is expected to close on
Independent DSMB has identified no safety concerns, to date, and recommends continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitorSixth consecutive positive DSMB recommendation to proceed highlights the favorable safety and tolerability of BriaCell's novel immunotherapy approach Phase 3 study is being conducted under FDA Fast Track Designation, reflecting the significant unmet need in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies t
Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ongoing Phase 3 study in heavily pre-treated metastatic breast cancer (MBC) patientsBiomarker analyses from the ongoing Phase 3 study confirm predictors of anti-cancer response seen in Phase 2 PHILADELPHIA and VANCOUVER, British Columbia, May 22, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce positive clinical data from three clinical data poster presentations and t
BriaCell expands push in women's health, building on Phase 2 success in advanced metastatic breast cancerBria-OVA+, BriaCell's next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S. PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care,
Bria-PROS+ is BriaCell's next generation personalized off-the-shelf immunotherapy for prostate cancerImmune stimulating components of Bria-PROS+ enhance anti-tumor responsesBriaCell has completed manufacturing clinical supplies of Bria-PROS+ and plans to initiate a Phase 1/2a clinical study in prostate cancer in the coming months PHILADELPHIA and VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it has completed manufacturing clinical supplies of Bria-PROS+, its next generatio
Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia (UVA) Comprehensive Cancer Center, Baptist Health South Florida, and SCRI Oncology Partners PHILADELPHIA and VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care is pleased to announce the addition of Penn Medicine's Abramson Cancer Center, an internationally recognized cancer center, as a clinical trial site in BriaCell's ongoing pivotal Phase 3 clinical study (Bri
Over 315 patients screened and over 230 patients enrolled in BriaCell's pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer Enrollment momentum continues with strong clinical site and patient interestInterim topline data expected in 2026Positive interim overall survival results could support potential approval of Bria-IMT in metastatic breast cancerBriaCell's Bria-IMT combination regimen continues under FDA Fast Track designation PHILADELPHIA and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company d
PHILADELPHIA and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care is pleased to announce the addition of NYU Langone Health's Laura and Isaac Perlmutter Cancer Center, a renowned cancer center in New York City, as a clinical trial site in its ongoing pivotal Phase 3 clinical study (Bria-ABC). BriaCell has enjoyed a marked uptick in interest from premier cancer centers and patient enrollment numbers following the prominent independent feature of its Phase 3 clinical trial in Nature Medicine's
Live Leadership Updates
PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL)) (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. ("BriaPro"), today announced the completion of the previously announced asset purchase transaction (the "Transaction") pursuant to a definitive purchase agreement dated February 4, 2026 (the "Purchase Agreement"), under which BriaPro acquired BriaCell's exclusive license to develop and commercialize Soluble CD80 ("sCD80") as a biologic agent for the treatment of c
PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL), BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2025 held on March 5, 2026 (the "Meeting"). A total of 48.31% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, co
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2024 held on February 5, 2025 (the "Meeting"). A total of 36.26% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company's Annual General Meeting of Shareholders (the "Meeting"), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the susp
VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaPro Therapeutics Corp. ("BriaPro" or the "Company"), a pre-clinical stage immunotherapy company developing binding agents and proteins with the intention to boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2023 held on January 30, 2024 (the "Meeting"). A total of 5,375,071 common shares of the Company (the "Common Shares") were voted, representing 33.63% of the Company's issued and outstanding Common Shares. At the Meeting, the Shareholders overwhelmingly voted in favour of all
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the formation of its medical advisory board and the appointment of three distinguished breast cancer key opinion leaders (KOLs) Massimo Cristofanilli, MD, FACP, Sara A. Hurvitz, MD, FACP, and Adam M. Brufsky, MD, PhD, as well as the addition of Charles Sidman, PhD, MBA, to its scientific advisory board. "We are extremely privileged to have these leading experts on state-of-the art breast cancer cli
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2022 held on February 9, 2023 (the "Meeting"). A total of 6,663,370 common shares of the Company (the "Common Shares") were voted, representing 42.94% of the Company's issued and outstanding Common Shares. At the Meeting, the Shareholders overwhelmingly voted in favour of all
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce that it has appointed leading immunologist, Alexander Kharazi, M.D., Ph.D., to its Scientific Advisory Board. Dr. Kharazi co-invented Bria-IMT™, BriaCell's lead clinical candidate, in collaboration with Dr. Charles L. Wiseman, BriaCell's Founder and Principal Research Advisor. Dr. Kharazi currently serves as Chief Technology Officer at Stemedica Cell Technologies, Inc. His experience include
Live finance-specific insights
The Company achieved revenue of $20.7 million during the year ended April 30, 2023, a 6.7% increase from the year ended April 30, 2022. YoY growth increases to 9.0% when adjusting for the effects of currency translation. The Company recorded total revenue of $5.6 million during the three months ended April 30, 2023, the highest quarterly revenue total the Company has recorded. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for the full fiscal year 2023 ended April 30, 2023. "As we usher in Fiscal Year 2024, we carry with us a strong momentum from the impressive
This live feed shows all institutional transactions in real time.
SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13G/A - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13G - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13G/A - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13G - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13G - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13G/A - BriaCell Therapeutics Corp. (0001610820) (Subject)